Page 1,538«..1020..1,5371,5381,5391,540..1,5501,560..»

Our Team – Stem Cell Therapy in Reno NV

Posted: July 6, 2017 at 5:41 am

Laurence McClish MD

Laurence McClish MD is a board-certified orthopedic surgeon and long-standing member of the American Academy of Orthopedic Surgeons. While practicing orthopedic surgery in the Reno area Dr. McClish also became board-certified in anti-aging medicine through the American Academy of Anti-Aging Medicine (A4M) in 2004. Dr. McClish retired from full- time orthopedic surgery in Reno in 2010 to pursue further studies in age management medicine.

Since 2010, Dr. McClish completed a Masters Degree in Metabolic and Nutritional Medicine through the University of South Florida Medical School, and received advanced fellowship training in Anti-Aging, Regenerative and Functional Medicine from A4M. Also, since 2010 he has pursued advanced studies in Stem Cell Therapy. He returned to practice part-time orthopedic surgery at William Bee Ririe Hospital in Ely, Nevada in late 2010, and he continues to practice routine orthopedics there today.

Dr. McClish practices stem cell medicine in Reno, Nevada. His main focus is in transferring a patients own stem cells into that same patients arthritic joint(s). While no statements can be made regarding the curing of arthritis, many patients report significant lessening of symptoms. Dr. McClish will be happy to share his results with you, while at the same time maintaining patient confidentiality.

.

Andrew C. Wesely MD

Dr. Andrew Wesely finished his primary training in Anesthesiology and Pain Management at the University of Alabama in Birmingham in 1993. He is Board Certified by the American Board of Anesthesiology with a Certificate of Added Qualification in Pain Management.

He has been practicing pain management in Reno since 1994, focusing primarily on nonoperative care for spinal pain and musculoskeletal disorders. Past and present professional affiliations include American society of Interventional Pain Physicians, Spine Intervention Society, American Society of Anesthesiologists, and the North American Neuromodulation Society.

Dr. Wesely has undergone specialized training in Regenerative Medicine including both BMAC and Lipoaspiration MSC harvesting techniques and laboratory methods, preparation and administration of PRP, Prolotherapy, Neural Prolotherapy, and the full spectrum of spinal and joint injections. He currently holds working appointments at several medical and surgical practices in the Reno area, and has clinical privileges at all major area hospital systems and ambulatory surgical centers.

.

Dr. Vincent C. Lombardi, phD

Dr. Vincent C. Lombardi, phD, currently serves as the Chief Scientific Officer for Sierra Stem Cell Institute. He also functions as the Director of Research at the Whittemore Peterson Institute for Neuro-Immune Disease, and has appointments within the University of Nevada School of Medicine, in Reno, Nevada. He brings an extensive research background in virology, microbiology, molecular biology, protein chemistry, and clinical diagnostics. He is the author or numerous scientific publications and has research experience in Fibromyalgia and Chronic Fatigue Syndrome.

The ability to apply current scientific findings into new diagnostic tools, procedures, and treatments for patients is known as Translational Medicine. Currently, a major push within the NIH is to leverage new technology and data analysis, along with collaboration between researchers and clinicians, to increase the speed at which new treatments reach patients. Dr. Lombardi serves Sierra Stem Cell Institute as the critical link between the basic science of stem cell biology, and their clinical application in patient care.

Read more from the original source:
Our Team - Stem Cell Therapy in Reno NV

Posted in Nevada Stem Cells | Comments Off on Our Team – Stem Cell Therapy in Reno NV

Nano Medicine

Posted: July 6, 2017 at 5:40 am

May 28th, 2017 Filed under Nano Medicine Tagged Comments Off on Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative

1 Research Methodology 1.1 Information procurement 1.2 Data Analysis 2 Executive Summary 3 Nanomedicine Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 3.1.1.1 Rising level of government participation in R&D funding 3.1.1.2 Introduction of technological advancements in diagnostic procedures 3.1.1.3 Rising usage of nanomedicine in drug delivery technology 3.1.2 Market restraint analysis 3.1.2.1 Side effects associated with intake of nanoparticles and lower adoption rate by patients 3.1.2.2 Hesitant uptake by medical and pharmaceutical industry 3.2 Penetration & Growth Prospect Mapping For Products, 2016 & 2025 3.3 Nanomedicine SWOT Analysis, By Factor (political & legal, economic and technological) 3.4 Industry Analysis Porters 4 Nanomedicine Market: Product Estimates & Trend Analysis 4.1 Nanomedicine market: product movement analysis 4.2 Therapeutics 4.2.1 Global therapeutics market, 2013 2025 (USD Billion) 4.3 Regenerative medicine 4.3.1 Global regenerative medicine market, 2013 2025 (USD Billion) 4.4 In-vitro diagnostics 4.4.1 Global in-vitro diagnostics market, 2013 2025 (USD Billion) 4.5 In-vivo diagnostics 4.5.1 Global in-vivo diagnostics market, 2013 2025 (USD Billion) 4.6 Vaccines 4.6.1 Global vaccines market, 2013 2025 (USD Billion) 5 Nanomedicine Market: Application Estimates & Trend Analysis 5.1 Nanomedicine market: Application movement analysis 5.2 Clinical oncology 5.2.1 Global clinical oncology market, 2013 2025 (USD Billion) 5.3 Infectious diseases 5.3.1 Global infectious diseases market, 2013 2025 (USD Billion) 5.4 Clinical cardiology 5.4.1 Global clinical cardiology market, 2013 2025 (USD Billion) 5.5 Orthopedics 5.5.1 Global orthopedics market, 2013 2025 (USD Billion) 5.6 Others 5.6.1 Global other applications market, 2013 2025 (USD Billion) 6 Nanomedicine Market: Nanomolecule Type Estimates & Trend Analysis 6.1 Nanomedicine Market: Nanomolecule Type Movement Analysis 6.2 Nanomolecules 6.2.1 Global nanomolecules market, 2013 2025 (USD Billion) 6.2.2 Nanoparticles & quantum dots 6.2.2.1 Global nanoparticles & quantum dots market, 2013 2025 (USD Billion) 6.2.2.2 Metal & metal compounds 6.2.2.2.1 Global metal & metal compounds nanoparticles market, by type nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.2 Gold nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.3 Silver nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.4 Alumina nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.5 Iron oxide nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.6 Gadolinium nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.2.7 Other metal & metal oxide nanoparticles market estimate & forecast, 2014 2025 (USD Billion) 6.2.2.3 Global metal & metal compound nanoparticles market, by application 6.2.2.3.1 In-vivo Imaging 6.2.2.3.2 Targeted drug delivery 6.2.2.3.3 Proton therapy 6.2.2.3.4 In-vitro assays 6.2.2.3.5 Cell & phantom imaging 6.2.2.4 Liposomes 6.2.2.4.1 Global liposomes market, 2013 2025 (USD Billion) 6.2.2.5 Polymer & polymer drug conjugates 6.2.2.5.1 Global polymer & polymer drug conjugates market, 2013 2025 (USD Billion) 6.2.2.6 Hydrogel nanoparticles 6.2.2.6.1 Global hydrogel nanoparticles market, 2013 2025 (USD Billion) 6.2.2.7 Dendrimers 6.2.2.7.1 Global dendrimers market, 2013 2025 (USD Billion) 6.2.2.8 Inorganic nanoparticles 6.2.2.8.1 Global inorganic nanoparticles market, 2013 2025 (USD Billion) 6.2.3 Nanoshells 6.2.3.1 Global nanoshells market, 2013 2025 (USD Billion) 6.2.4 Nanotubes 6.2.4.1 Global nanotubes market, 2013 2025 (USD Billion) 6.2.5 Nanodevices 6.2.5.1 Global nanodevices market, 2013 2025 (USD Billion) 7 Nanomedicine Market: Regional Estimates & Trend Analysis, by Product, Application, & Nanomolecule Type 7.1 Nanomedicine market share by region, 2016 & 2025 7.2 North America 7.2.1 North America nanomedicine market, 2013 2025 (USD Billion) 7.2.2 U.S. 7.2.2.1 U.S. nanomedicine market, 2013 2025 (USD Billion) 7.2.3 Canada 7.2.3.1 Canada nanomedicine market, 2013 2025 (USD Billion) 7.3 Europe 7.3.1 Europe nanomedicine market, 2013 2025 (USD Billion) 7.3.2 Germany 7.3.2.1 Germany nanomedicine market, 2013 2025 (USD Billion) 7.3.3 UK 7.3.3.1 UK nanomedicine market, 2013 2025 (USD Billion) 7.4 Asia Pacific. 7.4.1 Asia Pacific nanomedicine market, 2013 2025 (USD Billion) 7.4.2 Japan 7.4.2.1 Japan nanomedicine market, 2013 2025 (USD Billion) 7.4.3 China 7.4.3.1 China nanomedicine market, 2013 2025 (USD Billion) 7.5 Latin America 7.5.1 Latin America nanomedicine market, 2013 2025 (USD Billion) 7.5.2 Brazil 7.5.2.1 Brazil nanomedicine market, 2013 2025 (USD Billion) 7.6 Middle East & Africa 7.6.1 Middle East & Africa nanomedicine market, 2013 2025 (USD Billion) 7.6.2 South Africa 7.6.2.1 South Africa nanomedicine market, 2013 2025 (USD Billion) 8 Competitive Landscape 8.1 Strategy framework 8.2 Market participation categorization 8.3 Company Profiles 8.3.1 Arrowhead Pharmaceuticals, Inc. 8.3.1.1 Company overview 8.3.1.2 CALANDO PHARMACEUTICALS, Inc. 8.3.1.3 Financial performance 8.3.1.4 Product benchmarking 8.3.2 Brigham and Womens Hospital (BWH) 8.3.2.1 Company overview 8.3.2.2 Financial performance 8.3.2.3 Product benchmarking 8.3.3 Nanospectra Biosciences, Inc. 8.3.3.1 Company overview 8.3.3.2 Financial performance 8.3.3.3 Product benchmarking 8.3.4 ABLYNX 8.3.4.1 Company overview 8.3.4.2 Financial performance 8.3.4.3 Product benchmarking 8.3.4.4 Strategic initiatives 8.3.5 AMAG Pharmaceuticals 8.3.5.1 Company overview 8.3.5.2 Financial performance 8.3.5.3 Product benchmarking 8.3.5.4 Strategic initiatives 8.3.6 Bio-Gate AG 8.3.6.1 Company overview 8.3.6.2 Financial performance 8.3.6.3 Product benchmarking 8.3.6.4 Strategic initiatives 8.3.7 Celgene Corporation 8.3.7.1 Company overview 8.3.7.2 Abraxis BioScience, Inc. 8.3.7.3 Financial Performance 8.3.7.4 Product benchmarking 8.3.7.5 Strategic initiatives 8.3.8 Johnson & Johnson Services, Inc. 8.3.8.1 Company overview 8.3.8.2 Financial performance 8.3.8.3 Product benchmarking 8.3.8.4 Strategic initiatives 8.3.9 Pfizer, Inc. 8.3.9.1 Company overview 8.3.9.2 Financial performance 8.3.9.3 Product benchmarking 8.3.9.4 Strategic initiatives 8.3.10 Abbott 8.3.10.1 Company overview 8.3.10.2 Financial performance 8.3.10.3 Product benchmarking 8.3.10.4 Strategic initiatives 8.3.11 Leadiant Biosciences, Inc. 8.3.11.1 Company overview 8.3.11.2 Financial performance 8.3.11.3 Product benchmarking 8.3.11.4 Strategic initiatives 8.3.12 Teva Pharmaceutical Industries Ltd. 8.3.12.1 Company overview 8.3.12.2 Financial performance 8.3.12.3 Product benchmarking 8.3.13 CYTIMMUNE SCIENCES, INC. 8.3.13.1 Company overview 8.3.13.2 Financial performance 8.3.13.3 Product benchmarking 8.3.13.4 Strategic initiatives 8.3.14 Merck & Co Ltd 8.3.14.1 Company Overview 8.3.14.2 Financial performance 8.3.14.3 Product benchmarking 8.3.14.4 Strategic initiatives 8.3.15 Gilead 8.3.15.1 Company Overview 8.3.15.2 Financial performance 8.3.15.3 Product benchmarking 8.3.16 Epeius Biotechnologies Corporation 8.3.16.1 Company overview 8.3.16.2 Financial performance 8.3.16.3 Product benchmarking

List of Tables

Table 1 Nanofibers in Regenerative Medicine Table 2 North America nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 3 North America nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 4 North America nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 5 North America nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 6 North America nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 7 North America nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 8 North America nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 9 North America nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 10 North America metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 11 North America metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 12 North America metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 13 North America metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 14 Patent applicant for nanotechnology based therapeutics Table 15 U.S. nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 16 U.S. nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 17 U.S. nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 18 U.S. nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 19 U.S. nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 20 U.S. nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 21 U.S. nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 22 U.S. nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 23 U.S. metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 24 U.S. metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 25 U.S. metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 26 U.S. metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 27 Nanotechnology organizations which are involved in publishing nanoscience based articles Table 28 Canada nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 29 Canada nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 30 Canada nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 31 Canada nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 32 Canada nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 33 Canada nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 34 Canada nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 35 Canada nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 36 Canada metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 37 Canada metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 38 Canada metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 39 Canada metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 40 Europe nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 41 Europe nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 42 Europe nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 43 Europe nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 44 Europe nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 45 Europe nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 46 Europe nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 47 Europe nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 48 Europe metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 49 Europe metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 50 Europe metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 51 Europe metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 52 Germany nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 53 Germany nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 54 Germany nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 55 Germany nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 56 Germany nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 57 Germany nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 58 Germany nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 59 Germany nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 60 Germany metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 61 Germany metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 62 Germany metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 63 Germany metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 64 UK nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 65 UK nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 66 UK nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 67 UK nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 68 UK nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 69 UK nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 70 UK nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 71 UK nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 72 UK metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 73 UK metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 74 UK metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 75 UK metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 76 Asia Pacific nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 77 Asia Pacific nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 78 Asia Pacific nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 79 Asia Pacific nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 80 Asia Pacific nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 81 Asia Pacific nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 82 Asia Pacific nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 83 Asia Pacific nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 84 Asia Pacific metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 85 Asia Pacific metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 86 Asia Pacific metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 87 Asia Pacific metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 88 Japan nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 89 Japan nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 90 Japan nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 91 Japan nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 92 Japan nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 93 Japan nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 94 Japan nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 95 Japan nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 96 Japan metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 97 Japan metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 98 Japan metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 99 Japan metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 100 China nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 101 China nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 102 China nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 103 China nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 104 China nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 105 China nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 106 China nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 107 China nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 108 China metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 109 China metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 110 China metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 111 China metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 112 Latin America nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 113 Latin America nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 114 Latin America nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 115 Latin America nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 116 Latin America nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 117 Latin America nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 118 Latin America nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 119 Latin America nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 120 Latin America metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 121 Latin America metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 122 Latin America metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 123 Latin America metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 124 Brazil nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 125 Brazil nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 126 Brazil nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 127 Brazil nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 128 Brazil nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 129 Brazil nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 130 Brazil nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 131 Brazil nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 132 Brazil metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 133 Brazil metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 134 Brazil metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 135 Brazil metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 136 MEA nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 137 MEA nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 138 MEA nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 139 MEA nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 140 MEA nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 141 MEA nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 142 MEA nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 143 MEA nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 144 MEA metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 145 MEA metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 146 MEA metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 147 MEA metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion) Table 148 South Africa nanomedicine market estimates, by product, 2013 2016 (USD Billion)) Table 149 South Africa nanomedicine market forecasts, by product, 2017 2025 (USD Billion) Table 150 South Africa nanomedicine market estimates, by application, 2013 2016 (USD Billion) Table 151 South Africa nanomedicine market forecasts, by application, 2017 2025 (USD Billion) Table 152 South Africa nanomedicine market estimates, by nanomolecule type, 2013 2016 (USD Billion) Table 153 South Africa nanomedicine market forecasts, by nanomolecule type, 2017 2025 (USD Billion) Table 154 South Africa nanoparticle market estimates, by type, 2013 2016 (USD Billion) Table 155 South Africa nanoparticle market forecasts, by type, 2017 2025 (USD Billion) Table 156 South Africa metal and metal oxides nanoparticles market estimates, by type, 2013 2016 (USD Billion) Table 157 South Africa metal and metal oxides nanoparticles market forecasts, by type, 2017 2025 (USD Billion) Table 158 South Africa metal & metal oxides nanoparticles market estimates, by application, 2013 2016 (USD Billion) Table 159 South Africa metal & metal oxides nanoparticles market forecasts, by application, 2017 2025 (USD Billion)

List of Figures

Figure 1 Market research process Figure 2 Information procurement Figure 3 Primary research pattern Figure 4 Market research approaches Figure 5 Value chain based sizing & forecasting Figure 6 QFD modelling for market share assessment Figure 7 Market summary Figure 8 Market trends & outlook Figure 9 Market segmentation & scope Figure 10 Market driver relevance analysis (Current & future impact) Figure 11 Market restraint relevance analysis (Current & future impact) Figure 12 Penetration & growth prospect mapping for products, 2016 & 2025 Figure 13 SWOT Analysis, By Factor (political & legal, economic and technological) Figure 14 Porters Five Forces Analysis Figure 15 Nanomedicine market product outlook key takeaways Figure 16 Nanomedicine market: Product movement analysis Figure 17 Global therapeutics market, 2013 2025 (USD Billion) Figure 18 Global regenerative medicine market, 2013 2025 (USD Billion) Figure 19 Global in-vitro diagnostics market, 2013 2025 (USD Billion) Figure 20 Global in-vivo diagnostics market, 2013 2025 (USD Billion) Figure 21 Global vaccines market, 2013 2025 (USD Billion) Figure 22 Nanomedicine market: Application outlook key takeaways Figure 23 Global nanomedicine market: Application movement analysis Figure 24 Cancer cases per year Figure 25 Global clinical oncology market, 2013 2025 (USD Billion) Figure 26 Global infectious diseases market, 2013 2025 (USD Billion) Figure 27 Global clinical cardiology market, 2013 2025 (USD Billion) Figure 28 Global orthopedics market, 2013 2025 (USD Billion) Figure 29 Global other applications market, 2013 2025 (USD Billion) Figure 30 Nanomedicine market: Nanomolecule type outlook key takeaways Figure 31 Global nanomedicine market: Nanomolecule type movement analysis Figure 32 Global nanomolecules market, 2013 2025 (USD Billion) Figure 33 Global nanoparticles & quantum dots market, 2013 2025 (USD Billion) Figure 34 Global metal & metal compounds nanoparticles market, 2013 2025 (USD Billion) Figure 35 Global gold nanoparticles market, 2013 2025 (USD Billion) Figure 36 Global silver nanoparticles market, 2013 2025 (USD Billion) Figure 37 Global alumina nanoparticles market, 2013 2025 (USD Billion) Figure 38 Global iron oxide nanoparticles market, 2013 2025 (USD Billion) Figure 39 Global gadolinium nanoparticles market, 2013 2025 (USD Billion) Figure 40 Global other metal & metal oxide nanoparticles market, 2013 2025 (USD Billion) Figure 41 Global in-vivo imaging market, 2013 2025 (USD Billion) Figure 42 Global targeted drug delivery market, 2013 2025 (USD Billion) Figure 43 Global proton therapy market, 2013 2025 (USD Billion) Figure 44 Global in-vitro assays market, 2013 2025 (USD Billion) Figure 45 Global cell & phantom imaging market, 2013 2025 (USD Billion) Figure 46 Global liposomes market, 2013 2025 (USD Billion) Figure 47 Global polymer & polymer drug conjugates market, 2013 2025 (USD Billion) Figure 48 Global hydrogel nanoparticles market, 2013 2025 (USD Billion) Figure 49 Global dendrimers market, 2013 2025 (USD Billion) Figure 50 Global inorganic nanoparticles market, 2013 2025 (USD Billion) Figure 51 Global nanoshells market, 2013 2025 (USD Billion) Figure 52 Global nanotubes market, 2013 2025 (USD Billion) Figure 53 Global nanodevices market, 2013 2025 (USD Billion) Figure 54 Regional market place: Key take away Figure 55 Nanomedicine regional outlook, 2016 & 2025 Figure 56 North America nanomedicine market, 2013 2025 (USD Billion) Figure 57 U.S. nanomedicine market, 2013 2025 (USD Billion) Figure 58 Canada. nanomedicine market, 2013 2025 (USD Billion) Figure 59 Europe nanomedicine market, 2013 2025 (USD Billion) Figure 60 Germany nanomedicine market, 2013 2025 (USD Billion) Figure 61 UK nanomedicine market, 2013 2025 (USD Billion) Figure 62 Asia Pacific nanomedicine market, 2013 2025 (USD Billion) Figure 63 Japan nanomedicine market, 2013 2025 (USD Billion) Figure 64 China nanomedicine market, 2013 2025 (USD Billion) Figure 65 Latin America nanomedicine market, 2013 2025 (USD Billion) Figure 66 Brazil nanomedicine market, 2013 2025 (USD Billion) Figure 67 Middle East & Africa nanomedicine market, 2013 2025 (USD Billion) Figure 68 South Africa nanomedicine market, 2013 2025 (USD Billion) Figure 69 Strategy framework Figure 70 Participant categorization

See the original post: Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative

View post:
Nano Medicine

Posted in Nano medicine | Comments Off on Nano Medicine

Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Posted: July 6, 2017 at 5:40 am

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/6370

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Request to View Tables of Content @http://www.persistencemarketresearch.com/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

To Know About Latest Report Click Here:http://www.persistencemarketresearch.com/market-research/healthcare-nanotechnology-nanomedicine-market.asp

Read the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence ... - MilTech

Posted in Nano medicine | Comments Off on Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

Posted: July 6, 2017 at 5:40 am

July 3, 2017 by Ryan O'hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: "The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one."

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies's, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

"One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells," said Professor Mitchell. "We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells."

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

"In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung," explained Professor Mitchell. "This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery."

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to ...

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for ...

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

(Medical Xpress) -- Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive ...

(Phys.org)Neuroprostheses, neural probes and other intraneural tissue implants have offered remarkable benefits to recipients in a number of areas in neuroscience research and biomedical applications, therapeutic examples ...

As embedded intelligence is finding its way into ever more areas of our lives, fields ranging from autonomous driving to personalized medicine are generating huge amounts of data. But just as the flood of data is reaching ...

Squid-inspired proteins can act as programmable assemblers of 2D materials, like graphene oxide, to form hybrid materials with minute spacing between layers suitable for high-efficiency devices including flexible electronics, ...

(Phys.org)One of the most promising microscale power sources for portable and wearable electronics is a micro-supercapacitorthey can be made thin, lightweight, highly flexible, and with a high power density. Normally, ...

An international research team that includes University of Central Florida Professor Enrique del Barco, Damien Thompson of the University of Limerick and Christian A. Nijhuis of the National University of Singapore has cracked ...

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Nano-sized drug carriers could be the future for patients with lung disease - Phys.Org

Posted in Nano medicine | Comments Off on Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

Posted: July 6, 2017 at 5:40 am

June 30, 2017 Size switchable nano-theranostics constructed with decomposable inorganic nanomaterials for acidic TME targeted cancer therapy. (a) A scheme showing the preparation of HSA-MnO2-Ce6&Pt (HMCP) nanoparticles, and (b) their tumor microenvironment responsive dissociation to enable efficient intra-tumoral penetration of therapeutic albumin complexes. (c) A scheme showing the preparation of Ce6(Mn)@CaCO3-PEG, and (d) its acidic TME responsive dissociation for enhanced MR imaging and synergistic cancer therapy. Credit: Science China Press

Cancer is one of leading causes of human mortality around the world. The current mainstream cancer treatment modalities (e.g. surgery, chemotherapy and radiotherapy) only show limited treatment outcomes, partly owing to the complexities and heterogeneity of tumor biology. In recent decades, with the rapid advance of nanotechnology, nanomedicine has attracted increasing attention as promising for personalized medicine to enable more efficient and reliable cancer diagnosis and treatment.

Unlike normal cells energized via oxidative phosphorylation, tumor cells utilize the energy produced from oxygen-independent glycolysis for survival by adapting to insufficient tumor oxygen supply resulting from the heterogeneously distributed tumor vasculatures (also known as the Warburg effect). Via such oncogenic metabolism, tumor cells would produce a large amount of lactate along with excess protons and carbon dioxide, which collectively contribute to enhanced acidification of the extracellular TME with pH, often in the range of 6.5 to 6.8, leading to increased tumor metastasis and treatment resistance.

With rapid advances in nanotechnology, several catalogs of nanomaterials have been widely explored for the design of cancer-targeted nano-theranostics. In a new overview published in the Beijing-based National Science Review, co-authors Liangzhu Feng, Ziliang Dong, Danlei Tao, Yicheng Zhang and Zhuang Liu at the Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University in Suzhou, China present new developments in the design of novel multifunctional nano-theranostics for precision cancer nanomedicine by targeting the acidic TME and outline the potential development directions of future acidic tumor microenvironment-responsive nano-theranostics.

"Various types of pH-responsive nanoprobes have been developed to enable great signal amplification under slightly reduced pH within solid tumors. By taking the acidic TME as the target, smart imaging nanoprobes with excellent pH-responsive signal amplification would be promising to enable more sensitive and accurate tumor diagnosis," they state in the published study.

"As far as nano-therapeutics are concerned, it has been found that the acidic TME responsive surface charge reverse, PEG corona detachment and size shrinkage (or decomposition) of nanoparticles would facilitate the efficient tumor accumulation, intra-tumoral diffusion and tumor cellular uptake of therapeutics, leading to significantly improved cancer treatment. Therefore, the rational development of novel cancer-targeted nano-theranostics with sequential patterns of size switch from large to small, and surface charge reverse from neutral or slightly negative to positive within the tumor, would be more preferred for efficient tumor-targeted drug delivery."

The scientists also write, "For the translation of those interesting smart pH-responsive nano-therapeutics from bench to bedside, the formulation of those nanoscale systems should be relatively simple, reliable and with great biocompatibility, since many of those currently developed nano-theranostics were may be too complicated for clinical translation."

Explore further: Treatment with Alk5 inhibitor improves tumor uptake of imaging agents

More information: Liangzhu Feng et al, The acidic tumor microenvironment: a target for smart cancer nano-theranostics, National Science Review (2017). DOI: 10.1093/nsr/nwx062

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics - Medical Xpress

Posted in Nano medicine | Comments Off on Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

Stem Cell Charleston South Carolina 29401

Posted: July 4, 2017 at 4:44 pm

Stem cell therapy has ended up being a popular dispute in the worldwide medical scene. This highly questionable treatment has received blended opinions from different stakeholders in the health care industry and has actually also brought in the interest of political leaders, spiritual leaders and the general population at large. Stem cell therapy is considered an innovative treatment for people struggling with a wide range of degenerative conditions. Some typical concerns regarding this therapy are answered below.

Stem cells can be described as blank state or non-specialized cells that have the capability to become customized cells in the body such as bone, muscle, nerve or organ cells. This means that these unique cells can be used to regrow or establish a wide variety of damaged cells and tissues in the body. Stem cell treatment is for that reason a treatment that targets at accomplishing tissue regeneration and can be used to treat health conditions and illnesses such as osteoarthritis, degenerative disc illness, spinal cord injury, muscular degeneration, motor nerve cell disease, ALS, Parkinsons, cardiovascular disease and a lot more.

Stem cells can be extracted from a young embryo after conception. These stem cells are typically described as embryonic stem cells. After the stem cells are extracted from the embryo, the embryo is terminated. This is essentially among the significant reasons for debate in the field of stem cell studio. Many individuals argue that termination of an embryo is dishonest and unacceptable.

Stem cells can still be acquired through other ways as they can be discovered in the blood, bone marrow and umbilical cords of adult people. Typical body cells can also be reverse-engineered to become stem cells that have actually restricted capabilities.

Being a treatment that is still under studio, stem cell therapy has actually not been totally accepted as a practical treatment alternative for the above discussed health conditions and diseases. A lot of studio is presently being carried out by scientists and medical experts in various parts of the world to make this treatment sensible and efficient. There are nevertheless various restrictions enforced by federal governments on research involving embryonic stem cells.

Currently, there havent been lots of case studies performed for this kind of treatment. However, with the few case studies that have been carried out, one of the significant concerns that has been raised is the increase in a clients danger of developing cancer. Cancer is caused by the quick multiplication of cells that tend not to die so quickly. Stem cells have actually been connected with similar growth factors that may result in development of tumors and other malignant cells in clients.

New studio has actually nevertheless revealed pledge as scientists focus on establishing stem cells that do not form into growths in later treatment phases. These stem cells can therefore successfully transform into other types of specialized cells. This treatment is for that reason worth researching into as many patients can gain from this innovative treatment.

stem cell therapy in Charleston SC 29401

5 5

Main address: South Carolina

See the rest here:
Stem Cell Charleston South Carolina 29401

Posted in South Carolina Stem Cells | Comments Off on Stem Cell Charleston South Carolina 29401

Chris Rickert: Science skeptics shouldn’t steer UW hiring – Madison.com

Posted: July 4, 2017 at 12:47 am

The UW-Madison faculty group PROFS is not an unbiased source, given that its chief focus is to serve as a union-like advocate for better pay, tenure protections and other benefits for professors.

But in a letter last week to the Republican co-chairs of the committee that shapes the 2017-19 state budget, PROFS identifies threats to more than just the alleged cushiness of its members positions.

Specifically, efforts to shape or influence the hiring of top administrators at one of the most well-regarded seekers of knowledge in the country do not inspire confidence when coming from those with a questionable faith in academic rigor.

Non-eggheads shouldnt be barred from seeking higher ed employment, and its not new for people from the worlds of business and government in particular to get hired as university presidents and chancellors.

I couldnt find any research on whether they are any better or worse for higher education than lifelong academics, but people like former Arizona Gov. and U.S. Cabinet official Janet Napolitano at the University of California, and former Indiana Gov. Mitch Daniels at Purdue dont seem to have left the places in ruin.

As for the Thompson Center, UW-Madison political science professor Ryan Owens, one of the Centers chief proponents, acknowledged that the process for hiring the centers director veers from the norm at UW-Madison. He also wasnt sure Thursday whether the center would need to go through the same internal process UW-Madison has used to approve other university centers.

But he reiterated that the center absolutely will be research-based and objective in practice.

The peoples elected representatives should have some say in the staffing of a public institution that gets more than $1 billion of taxpayer money a year. (Although given the intense gerrymandering of Assembly districts, the elected representatives arent nearly as representative as they should be.)

The problem in emphasizing nonacademic applicants to academia and in giving politicians more control over an academic hire is that the current crop of people pushing such ideas are the same people who, by their actions, tend to deride two core, interrelated functions of academia: research and the scientific method.

In the UW System, the System president and the chancellors are hired by the 18-member Board of Regents. Sixteen of those Regents are appointed by the governor, with consent of the Senate. And obviously, the governor, Assembly and Senate get major say in the budget.

The current governor, Scott Walker, oversees a Department of Natural Resources that has eliminated scientist positions and scrubbed scientifically backed language from its website identifying humans as a primary source of climate change.

State Sen. Tom Tiffany is an admitted climate change skeptic, while Sen. Alberta Darling and one of Walkers appointees to the Regents, Margaret Farrow, were part of the Wisconsin Women for Trump coalition that worked on behalf of a man whose climate change skepticism and well-documented aversion to the facts didnt keep him from becoming president.

Walker has signed a bill outlawing abortions beyond 20 weeks of gestation based on the unscientific contention that fetuses that young can feel pain, and in explaining opposition to research with embryonic cells or fetal tissue, he and Rep. Andr Jacque have promulgated scientifically questionable notions about the usefulness of adult stem cell research.

Republicans have also passed and mounted a failed defense of a law requiring abortion doctors to have hospital admitting privileges, despite medical sciences opinion that such a requirement does nothing to protect patients.

Perhaps the most egregious denial of the scientific method comes from Rep. Jesse Kremer, who has said its a fact that the Earth is 6,000 years old.

To be clear, its all well and good to have a variety of opinions on the importance of fossil fuels to the economy, or on whether abortion is moral or the Bible adds meaning to life.

But people unwilling to accept the widely accepted results of widely used and rigorous academic research methods probably shouldnt be messing around with academia.

Follow this link:
Chris Rickert: Science skeptics shouldn't steer UW hiring - Madison.com

Posted in Indiana Stem Cells | Comments Off on Chris Rickert: Science skeptics shouldn’t steer UW hiring – Madison.com

Stem Cell Therapy – Neuropathy & Pain Centers of Texas

Posted: July 4, 2017 at 12:46 am

At Neuropathy & Pain Centers of Texas, non-invasive medical procedures are the mainstay of our practice. Using the most up to date techniques, our staff treats patients as whole people, providing a comprehensive diagnostic assessment in order to design a customized strategy for relief from medical concerns in the Dallas/Fort Worth area. The technology has advanced to a point that, at Neuropathy & Pain Centers of Texas, we apply stem cell treatments designed to help our patients attain their wellness goals and achieve a higher quality of life.

For instance, until recently, treatment options for people with osteoarthritis of the knee were limited. Steroid injections, joint replacement surgery, and physical therapy were often the only treatment options. Now, regenerative injections for knee osteoarthritis are available at Neuropathy & Pain Centers of Texas. Regenerative cellular therapy also has applications for treating Achilles tendonitis, rotator cuff tendonitis, and degenerative arthritis.

These injections work with the bodys natural ability to heal itself. Unlike treatments that simply address the symptoms, stem cell therapy actually promotes repair of the body, restoring degenerated tissue. Stem cell injections also contain hyaluronan, which eases pain and restores mobility by lubricating joints and tendons. This therapy fits well with Neuropathy & Pain Centers of Texass integrated approach to wellness, addressing the source of issues, rather than just treating the symptoms.

Read this article:
Stem Cell Therapy - Neuropathy & Pain Centers of Texas

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy – Neuropathy & Pain Centers of Texas

Stem cell-based therapies to treat spinal cord injury: a review – Dove Medical Press

Posted: July 4, 2017 at 12:46 am

Zhongju Shi,1,2 Hongyun Huang,3 Shiqing Feng1,2

1Department of Orthopaedics, Tianjin Medical University General Hospital, 2Institute of Neurology, Key Laboratory of Post-Neuroinjury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin City, Tianjin, 3Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing, Peoples Republic of China

Abstract: Spinal cord injury (SCI) is a devastating condition and major burden on society and individuals. Currently, neurorestorative strategies, including stem cell therapy products or mature/functionally differentiated cell-derived cell therapy products, can restore patients with chronic complete SCI to some degree of neurological functions. The stem cells for neurorestoration include neural stem cells, mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, etc. A better understanding of the merits, demerits and precise function of different stem cells in the treatment of SCI may aid in the development of neurorestorative strategies. However, the efficacy, safety and ethical concerns of stem cell-based therapy continue to be challenged. Nonetheless, stem cell-based therapies hold promise of widespread applications, particularly in areas of SCI, and have the potential to be novel therapeutics, which contributes to the repair of SCI. This review mainly focused on recent advances regarding the stem cell-based therapies in the treatment of SCI and discussed future perspectives in this field.

Keywords: spinal cord injury, neural stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells, induced pluripotent stem cells

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Stem cell-based therapies to treat spinal cord injury: a review - Dove Medical Press

Posted in Stem Cell Therapy | Comments Off on Stem cell-based therapies to treat spinal cord injury: a review – Dove Medical Press

Stem cell therapy to treat paralytic dogs draws pet owners from … – Times of India

Posted: July 4, 2017 at 12:46 am

Bareilly: Dog owners from across the country, including Delhi and Gujarat, are turning up with their paralytic pets at the Indian Veterinary Research Institute (IVRI) here for stem cell therapy. Scientists treat a paralyzed dog by transplanting stem cells from healthy dogs. IVRI is the second institute in the country to offer this treatment, after Madras Veterinary College, Chennai.

According to scientists, no research has been conducted to determine the number of dogs who suffer from paralysis every year in India. However, the institute receives at least four cases every week of spinal trauma which causes paralysis in dogs. IVRI recorded 143 cases of posterior paralysis in 2016. These were treated with stem cell therapy and medicines.

If dogs are treated only with medicines, recovery is witnessed only in a few cases, said Amarpal (who goes by his first name), head and principal scientist, division of surgery, IVRI. On an average, 17% recovery rate was noted among dogs administered only medicines.

However, the best response was recorded among severely affected dogs when they were treated using stem cells, where almost all the patients responded to treatment to variable extent, said the scientist. Though we have cases where recovery was 100%, the average recovery rate is about 50%. The experiment proved the efficacy of stem cell therapy in cases of paralysis due to spinal trauma, said Amarpal.

The paralytic dog is first administered anesthesia before the stem cells are injected into its spinal cord. It takes only one session for a dog to undergo the therapy and it is discharged the same day.. After this, the owner has to bring his pet for check-ups for two or more times so that vets can monitor how the animal is responding to the treatment and if it is suffering from any reaction, said Amarpal.

Read the rest here:
Stem cell therapy to treat paralytic dogs draws pet owners from ... - Times of India

Posted in Stem Cell Therapy | Comments Off on Stem cell therapy to treat paralytic dogs draws pet owners from … – Times of India

Page 1,538«..1020..1,5371,5381,5391,540..1,5501,560..»